Sanofi-Aventis Receives Complete Response Letter from the FDA for Eplivanserin (Ciltyri(R)) Submission
Sanofi-Aventis Receives Complete Response Letter from the FDA for Eplivanserin (Ciltyri(R)) Submission BRIDGEWATER, N.J., Sept. 16 /PRNewswire-FirstCall/ — Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the company’s New Drug Application (NDA) for eplivanserin (Ciltyri ). Eplivanserin was reviewed as a potential treatment for patients with chronic insomnia characterized by difficultie